Evaluating the prognostic value of miR-148/152 family in cancers: based on a systemic review of observational studies

Fujiao Duan _, Weigang Liu, Xiaoli Fu, Yajing Feng, Liping Dai, Shuli Cui and Zhenxing Yang

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:77999-78010. https://doi.org/10.18632/oncotarget.20830

Metrics: PDF 1146 views  |   HTML 1893 views  |   ?  


Fujiao Duan1,2,6, Weigang Liu3, Xiaoli Fu2, Yajing Feng2,4, Liping Dai2,6, Shuli Cui5 and Zhenxing Yang1

1Medical Research Office, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, China

2College of Public Health, Zhengzhou University, Zhengzhou, Henan, China

3Medical Record Statistics Office, Affiliated Hospital of Hebei University of Engineering, Handan, Hebei, China

4Department of Nosocomial Infection Management, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China

5College of Professional Study, Northeastern University, Boston, Massachusetts, USA

6Henan Key Laboratory of Tumor Epidemiology, Zhengzhou, Henan, China

Correspondence to:

Fujiao Duan, email: [email protected]

Zhenxing Yang, email: [email protected]

Keywords: miR-148/152 family, prognosis, cancer, systems assessment

Received: July 14, 2017     Accepted: August 27, 2017     Published: September 11, 2017


Background: The prognostic significance of MicroRNA-148/152 (miR-148/152) family expression in various cancers has been investigated by many studies with inconsistent results. To address this issue, we performed a meta-analysis to clarify this relationship.

Materials and Methods: Eligible studies were recruited by a systematic literature search and assessed the quality of included studies based on Quality In Prognosis Studies (QUIPS) and Newcastle-Ottawa Scale (NOS). Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) for overall survival (OS) and disease free survival/progressive free survival/recurrence free survival (DFS/PFS/RFS) were calculated to estimate the effects of miR-148/152 family expression on prognosis.

Results: A final total of 23 articles (26 studies) were considered in evidence synthesis. A significant association was observed between low miR-148a level and poor OS in patients (HR = 1.59, 95% CI: 1.14 – 2.20, P = 0.00), especially with digestive tract cancer (DTC) (HR = 1.29, 95% CI: 1.03–1.63, P = 0.03), and another significant association was observed between low miR-148b level and poor OS in patients (HR=2.09, 95% CI: 1.70–2.56, P = 0.00), especially with (hepatocellular carcinoma) HCC (HR = 1.97, 95% Cl: 1.52–2.56, P = 0.00) and non-small cell lung cancer (NSCLC) (HR = 2.29, 95% Cl: 1.64–3.18, P = 0.00). The significant correlation between miR-152 and DFS/RFS was found in our research (HR = 3.49, 95% Cl: 1.13–10.08, P = 0.03).

Conclusions: Our findings suggest that low miR-148/152 family expression is significantly associated with poor prognosis and may be a feasible prognostic biomarker in some cancers, especially in HCC and NSCLC.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 20830